🔎 Trials Near Me

Home › Cystic Fibrosis › NCT06683092

Restarting Triple Therapy With Robust Monitoring for Adverse Events (RETRIAL)

RecruitingObservational study

Who can join

Ages 6 and older · All sexes

Full eligibility criteria
Inclusion Criteria:

RETRIAL-Mental Health:

* PWCF age 6 years and up (if age is \< 12 years old, the PWCF's caregiver will complete daily diaries and surveys; see "Caregiver Participant Inclusion Criteria" below)
* Eligible for VTD and intending to take it
* Experienced new or worsening mental health symptoms after initiating ETI, which led to one of the following changes in treatment to currently taking:

  1. No modulators
  2. A modulator other than ETI
  3. A flipped dose of ETI
  4. A reduced dose of ETI
* Willing to delay first VTD dose for short period of time to complete the Baseline assessments
* Has access to a smart device (phone, tablet, etc.) capable of receiving messages with survey links
* Is English-speaking.

RETRIAL-LIVER:

* A person with CF age 6 years and up
* Eligible for VTD and intending to take it
* Experienced drug-induced liver injury (as defined by local care team) after initiating ETI, which led to one of the following changes in treatment to currently taking:

  1. no modulators; or
  2. a modulator other than ETI; or
  3. a reduced or altered dose of ETI;
* Willing to delay first VTD dose for short period of time to complete the Baseline assessments
* Has access to a smart device (phone, tablet, etc.) capable of receiving messages with survey links
* Is English-speaking.

Exclusion Criteria:

RETRIAL-Mental Health:

* Cannot access VTD
* Currently, or prior history of, taking VTD
* Unable or unwilling to follow protocol
* If \<12 years old, having another \<12-year-old person in the same household consented into the study
* Is actively listed on any transplant list, or within 3 months post-transplant surgery
* Is currently pregnant (test not required)
* Anticipated change in CF Care Centers in the next 6 months
* Any situation that, in the opinion of the Investigator, would compromise the safety of the patient or the quality of the data.

RETRIAL-LIVER:

* Cannot access VTD
* Currently, or prior history of, taking VTD
* Unable or unwilling to follow protocol
* If \<12 years old, having another \<12-year-old person in the same household consented into the study
* Any severe, decompensated liver disease (e.g. Child-Pugh, Class C)
* Is actively listed on any transplant list, or within 3 months post-transplant surgery (any organ), or history of liver transplant
* Is currently pregnant (test not required)
* Anticipated change in CF Care Centers in the next 6 months
* Any situation that, in the opinion of the Investigator, would compromise the safety of the patient or the quality of the data.

Caregiver Participant:

Inclusion Criteria:

* Is a primary, daily caregiver of a person with CF under the age of 12 enrolled in the study
* Has access to smart device (phone, tablet, etc.) capable of receiving messages with survey links
* Is able to read and complete surveys and Daily Diary in English.

Exclusion Criteria:

\- Any situation that, in the opinion of the Investigator, would compromise the safety of the patient or the quality of the data.

About the study

RETRIAL is a multi-site observational study of people with Cystic Fibrosis (PWCF) ages 6 and up starting the new triple-therapy modulator (vanzacaftor/tezacaftor/deutivacaftor (VTD)), after having experienced neuropsychiatric events and/or liver injury while taking elexacaftor/tezacaftor/ivacaftor (ETI) that resulted in a modification or discontinuation of standard ETI dosing.

What is being tested

Sponsor: Boston Children's Hospital · Participants: 200 · Started: May 1, 2025

Contact the study team

Official record on ClinicalTrials.gov — NCT06683092

Locations in the U.S.

AlabamaUniversity of Alabama at Birmingham, Birmingham
ColoradoChildren's Hospital Colorado, Aurora
National Jewish Health, Denver
DelawareNemours Children's, Wilmington
FloridaNemours Children's, Jacksonville
Nemours Children's, Orlando
Nemours Children's, Pensacola
GeorgiaEmory University, Atlanta
IndianaIndiana University, Bloomington
KansasKansas University Medical Center, Kansas City
MarylandJohns Hopkins University, Baltimore
MassachusettsBoston Children's Hospital, Boston
Massachusetts General Hospital, Boston (Not yet recruiting)
MichiganUniversity of Michigan, Ann Arbor
MissouriWashington University at St. Louis, St Louis (Not yet recruiting)
PennsylvaniaUniversity of Pittsburgh Medical Center, Pittsburgh
TexasUniversity of Texas Southwestern Medical Center, Dallas
WashingtonSeattle Children's Hospital, Seattle

Conditions

From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.